Johnson & Johnson presented significant clinical data at ASCO 2026, featuring promising results for nipocalimab and practice-changing Phase 3 outcomes in prostate cancer and myeloma. The company also announced a $1 billion acquisition of Firefly Bio to access its specialized platform for targeting KRAS-driven tumors. Furthermore, new data showed that the Talvey and Darzalex Faspro combination reduced disease progression risk by 72% in earlier-stage multiple myeloma.
J&J's combination therapy reduced disease progression risk by 72% in early-stage multiple myeloma patients, according to Phase 3 data presented at the EHA Congress.
Read the full storyJohnson & Johnson strengthens its oncology portfolio by acquiring the Firelink platform to target difficult-to-treat genetic mutations.
The company unveiled positive data for nipocalimab and innovative prostate cancer treatments, reinforcing its expansion strategy in oncology and immunology.